|
|
Upfront Briefing
Ultragenyx finally got its Sanfilippo approval — two days early, full approval rather than the accelerated nod it asked for, and a priority review voucher in the bag. Novo wrote a $1.4B biobucks cheque for Orbis’ oral macrocycles without disclosing a single number underneath it, and Roche put $36.5M down on screening 300,000 bispecific combinations.
The financing window is doing its best 2021 impression: two reverse mergers and an upsized IPO in one session, $755M of fresh paper between them. Elsewhere, policy stayed clear as mud, with pharma tariff rules unresolved 12 days before go-live.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,637.8 |
+1.1% |
+11.6% |
| Nasdaq 100 |
29,447.0 |
+1.7% |
+16.8% |
| Russell 2000 |
2,874.6 |
+0.6% |
+15.8% |
| Healthcare (XLV) |
168.8 |
+0.6% |
+9.1% |
| Biotech (XBI) |
158.2 |
+2.6% |
+29.8% |
| Nasdaq Biotech (NBI) |
7,058.8 |
+2.2% |
+23.7% |
| Clinical Trials (BBC) |
49.2 |
+2.2% |
+30.9% |
|
- Biotech led, and it was beta rather than defensives: XBI +2.6%, NBI +2.2% and BBC +2.2% against XLV’s +0.6% and the S&P 500’s +1.1%.
- The broader bid came from crude and the long end: Brent slipped to about $104 on signs Saudi supply is set to re-flow, and TLT added 1.1% as the 10-year backed off the 2007 high it touched on Wednesday. First session after the Fed’s 25bp hike to 3.75%–4.00%.
- Market data: U.S. cash close Thursday, 17 September 2026.
The Big 3
- The FDA granted standard full approval to Fayuvi (rebisufligene etisparvovec-hopf), the AAV9 gene therapy known as UX111, for paediatric MPS IIIA with preserved neurodevelopmental function — two days ahead of the 19 September PDUFA and against a resubmission that had sought accelerated approval. Product ships to qualified treatment centres in 30–60 days.
- Why it matters: Full approval, not the accelerated nod Ultragenyx asked for, on a resubmission that followed a July 2025 CRL over manufacturing — the Bedford CMC fix cleared inspection in August and this approval is the receipt. The commercial line is thin: 1,500–2,500 US patients and 6,000–8,000 worldwide, so Fayuvi is a validation asset, not a revenue story. The priority review voucher granted alongside it is the nearer-term cash and is separately saleable to a peer. Second gene therapy approval and sixth FDA nod overall for RARE, which answers the platform question that hung over the stock through 2025.
- Source: Endpoints
- More: STAT; Fierce Pharma
|
|
2
|
Novo, Orbis strike up to $1.4B oral macrocycle deal
|
- Novo Nordisk signed a multi-target discovery and licensing agreement with Denmark’s Orbis Medicines worth up to $1.4B in upfront and milestone payments, plus tiered royalties and an undisclosed strategic equity investment. Neither the targets nor the split between upfront and milestones was disclosed; Orbis’ nGen platform has reached up to 18% oral bioavailability in preclinical work.
- Why it matters: Read $1.4B as a ceiling, not a cheque. Neither side broke out the upfront, and on a discovery-stage multi-target deal the overwhelming majority of that number sits behind preclinical, clinical and sales gates. What is disclosed matters more: Novo is buying a shot at oral delivery for targets its SNAC peptide technology, acquired with Emisphere in 2020, cannot reach. Novo Holdings seeded Orbis in 2021 and joined the €90M Series A in January 2025, so this is an insider adding, not a contested process; Lilly also sits on the register. Hanmi/Genentech put $190M upfront against $2.31B. This one names no floor at all.
- Source: BioSpace
- More: BioPharma Dive; Fierce Biotech
|
| 3 | North Immunology takes $180M and a Nasdaq shell at Dupixent |
- ADAR1-incubated North Immunology will go public through an all-stock reverse merger with Aethlon Medical, alongside a $180M oversubscribed private placement — roughly $146M of new money plus about $34M of converting notes. AEMD rose 471%. Lead asset NOR-101, a half-life-extended IL-13 x IL-18 bispecific, enters Phase 1a in Q1 2027; North holders take 95.25% and Aethlon holders 4.75% plus a CVR on the legacy Hemopurifier business. Ticker becomes NRTX.
- Why it matters: The financing is the story, not the science. This is roughly the twenty-fourth biotech reverse merger of 2026 and it lands the same session Lisata took in Marea with a $225M placement and Electra priced an upsized $350M IPO. Bain Capital Life Sciences, Janus Henderson, Deep Track, Longitude, Soleus, Invus, Farallon, Adage and TCGX all bought paper in a preclinical asset, which is the crossover bid telling you it will fund 2028 data. The comps are Slate/Fulcrum at $245M, Avenzo/Rallybio at $215M and Avere/NextCure at $320M. NOR-101 adds IL-18 blockade to the IL-13 axis Dupixent owns, aimed at the non-type-2 patients biologics miss; no human data until mid-2027.
- Source: STAT
- More: BioPharma Dive; Fierce Biotech
|
Everything Else that broke
- Bayer’s Kerendia (finerenone) won a third FDA indication, for CKD associated with type 1 diabetes and the first new option in over 30 years, on the Phase 3 FINE-ONE UACR endpoint; hyperkalemia ran 10.1% versus 3.3% on placebo. — Fierce Pharma
- Roche will pay Dualitas $36.5M upfront, against up to $1B in milestones plus tiered royalties, to screen more than 300,000 bispecific combinations for immunology and inflammation. — Endpoints
- Lisata acquired Marea stock-for-stock alongside a $225M private placement, leaving pre-deal Lisata holders with 2.39% and pivoting the company to cardioendocrine assets; LSTA rose about 20%. — Fierce Biotech
- Pharma tariff exemptions are still unresolved with 12 days left before implementation. — BioCentury
- Roche posted a positive confirmatory Phase 3 readout for Lunsumio in follicular lymphoma, supporting label expansion and conversion to full approval. — Endpoints
- Bristol Myers dropped BMS-986497/ORM-6151 after a Phase 1 look, ending the $100M Orum-partnered oncology programme. — Endpoints
- CMS may exempt drugmakers from two pricing demos if they offer extra Medicaid rebates. — Endpoints
- Six UK committees want a probe into the cost of the US pharma trade deal. — Endpoints
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Novo Nordisk / Orbis Medicines — up to $1.4B in upfront and milestones, tiered royalties, undisclosed strategic equity; oral macrocycles for cardiometabolic targets (see The Big 3). — BioSpace
- Roche / Dualitas Therapeutics — $36.5M upfront, up to $1B total, tiered royalties; DualScreen bispecific discovery for I&I. — Endpoints
- SK Biopharmaceuticals / 1ST Biotherapeutics — $1.8M upfront plus a $1.8M candidate-selection milestone, up to $314.8M total and tiered royalties, with a separate $2.2M equity investment; preclinical LRRK2/c-Abl dual inhibitor 1ST-104 in Parkinson’s. — Fierce Biotech
VC / Private Financings
- No notable VC or private financings in the last 24 hours.
IPOs / Follow-Ons
- Electra Therapeutics (ETRA) — upsized IPO priced at 23,333,334 shares at $15.00 for $350M gross, against terms of 21.67M at $14–16; 3.5M-share greenshoe, trades today, closes 21 September. Jefferies, TD Cowen, Evercore ISI and Cantor. Ipsoprubart is in the registrational Phase 2/3 SURPASS trial in sHLH, enrolment completing 2H27. — Endpoints
- North Immunology / Aethlon — $180M oversubscribed private placement, about $146M new capital plus roughly $34M of converting notes; Bain Capital Life Sciences, Janus Henderson, Deep Track, Longitude, Soleus, Invus, Farallon, Adage, TCGX. — PR
- Lisata (LSTA) — $225M concurrent private placement in Series C non-voting convertible preferred at about $1.4914 per as-converted share; conversion subject to a stockholder vote. Jefferies, Leerink, Guggenheim, Cantor and LifeSci as placement agents. — PR
- Halozyme (HALO) — upsized $1.3B of 1.50% convertible senior notes due 2033 priced, against the $1.05B launched on 17 September. — PR
Academic Corner
- Large-insertion gene editing drew a fresh expert review on delivery, efficiency and safety tradeoffs for therapeutic genome engineering. — Nature Biotech
- Lancet correspondence spotlighted emergency presentations as an overlooked driver of inequity in ovarian cancer care. — Lancet
|
|
Two reverse mergers, an upsized IPO and a free voucher, all before lunch. Have a weekend.
— BioBucks Team
|
|
|
